ClinicalTrials.gg
CompletedNCT00595231Updated Feb 27, 2019Results posted

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

A Phase 2 interventional study of SYN111 and Placebo in Generalized Anxiety Disorder, sponsored by Biotie Therapies Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-02-27.

Sponsored by Biotie Therapies Inc. (part of Acorda Therapeutics) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
70th of 234
239 · median 90
Started
2008
with 19 others
Phase 2
21 of 265
5 open now
Registered
48th of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 70th largest by enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2008, is one of 21 in phase 2, and was the 48th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.

Read the detailed description

This was an exploratory study to evaluate the effect of 500 or 1000 mg per day for 8 weeks of Rufinamide compared to placebo on measures of anxiety in patients with Generalized Anxiety Disorder, and to determine tolerability of Rufinamide in this population.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • GAD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient 18-65
  • Meet Diagnostic and Statistical Manual,(DSM) IV criteria for GAD
  • Have moderate to severe anxiety
  • Sign IRB (Institutional Review Board) approved consent and can comply with visits and procedures
  • Women of must use acceptable method of

Exclusion criteria

Exclusion Criteria:

  • Have diagnosis of adjustment disorder or anxiety disorder Not otherwise specified (NOS)
  • Have diagnosis of specific phobia
  • Have diagnosis of antisocial personality disorder or other Axis II Disorder
  • Have diagnosis of substance abuse disorder within 3 months of study entry
  • Have diagnosis of major depressive disorder or panic disorder within 6 months of study entry
  • Have diagnosis of PTSD, eating disorder substance dependence disorder within 12 months of study entry
  • Have diagnosis anytime during lifetime of schizophrenia or other psychotic disorder, bipolar mood disorder, Obsessive-Compulsive Disorder (OCD), psychosurgery
  • Require medication to treat GAD other than study medication
  • Failed to show improvement with past treatment for GAD
  • Excessively consume caffeine
  • Are receiving treatment with prohibited medications
  • Uncontrolled thyroid condition
  • Positive urine drug screen
  • Obese
  • finding
  • Participating in other clinical trial
  • Clinically significant out of range lab value
  • Past exposure to rufinamide
  • Pregnant or nursing females
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    SYN111

    500 mg 1 week, followed by 1000 mg for 7 weeks

    Drug: SYN111

  • Placebo comparator
    Placebo

    0 mg tablets

    Drug: Placebo

Interventions

  • DrugSYN111

    500 mg for 1 week followed by 1000 mg for 7 weeks

    Also known as: Rufinamide

  • DrugPlacebo

    0 mg tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed

    The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.

    Time frame: 8 Weeks

  2. Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics

    The Hospital Anxiety and Depression Scale is a self screening questionnaire for depression and anxiety. It consists of 14 questions, seven for anxiety and seven for depression. The 14 statements are relevant to either generalized anxiety (7 statements) or 'depression' (again 7). Each question has 4 possible responses. Responses are scored on a scale from 3 to 0. The maximum score is therefore 21 for depression and 21 for anxiety. A score of 11 or higher indicates the probable presence of the mood disorder with a score of 8 to 10 being just suggestive of the presence of the respective state. The 2 subscales, anxiety and depression, have been found to be independent measures. In its current form the HADS is now divided into 4 ranges: normal (0-7), mild (8-10), moderate (11-15) and severe (16-21). Anxiety score = sum of items 1, 3, 5, 7, 9, 11, and 13. Depression score = sum of items 2, 4, 6, 8, 10, 12, and 14.

    Time frame: 8 Weeks

  3. Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.

    The MADRS (Montgomery and Asberg 1979) is a clinician-rated instrument that measures the presence and severity of depression. This instrument consists of 10 items. Each item is rated on a defined step scale of 0 to 6 with anchors at 2-point intervals. The MADRS total score is the sum of the 10 items and ranges from 0 to 60. A high numeric rating shows a greater degree of symptom severity.

    Time frame: 8 Weeks

  4. Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)

    Severity of illness is the first scale in the CGI. A rating is filled in by the investigator at the start of treatment based on a 0-7 point weighted scale. It goes from not assessed (0), to among the most extremely ill patients (7).

    Time frame: 8 weeks

  5. Change From Baseline Raskin Depression Scale.

    It explores the extent to which an individual demonstrates depression on three sub-scales (rated 1-5): verbal self-report, behavior and secondary symptoms of depression. Scores range from 3-15, with higher scores indicating greater severity.

    Time frame: 8 weeks

  6. Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed

    The Covi Anxiety Scale is a simple 3 item scale for the assessment of severity of anxiety symptoms. The scale measures 3 dimensions: verbal report, behavior and somatic symptoms of anxiety. Each item scored on a scale of 1 - 5. (1)not at all, (2)somewhat, (3)moderately, (4) considerably, and (5)very much), hence the scale is a 5- to 15 point range. The three items are the patient's verbal report (feeling shaky, jittery, jumpy), observed behavior consistent with anxiety during the interview (e.g. appearing frightened, shaky, restless) and somatic complains (e.g., sweating, trembling, heart pounding). COVI Rating Scale total score is the sum of items 1 - 3.

    Time frame: 8 weeks

07

Results

Posted Jan 23, 2019

Participant flow

A total of 239 subjects were randomized into the trial from 19 of the 20 study sites initiated.

Participant flow — Overall Study
MilestoneRufinamidePlacebo
Started120119
Completed115114
Not completed55

Outcome measures

PrimaryChange From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed

The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.

Time frame:
8 Weeks
Reported as:
Mean · score on a scale
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
score on a scaleRufinamidePlacebo
Screening25.5 ± 3.7025.6 ± 3.77
Baseline25.5 ± 3.7725.8 ± 3.74
Week 121.9 ± 6.0421.4 ± 5.71
Week 220.0 ± 6.2919.6 ± 5.97
Week 318.0 ± 7.4517.8 ± 7.02
Week 615.7 ± 7.3416.7 ± 7.32
Week 815.1 ± 7.7615.1 ± 7.19
Last Observation16.7 ± 7.9116.1 ± 7.65
PrimaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics

The Hospital Anxiety and Depression Scale is a self screening questionnaire for depression and anxiety. It consists of 14 questions, seven for anxiety and seven for depression. The 14 statements are relevant to either generalized anxiety (7 statements) or 'depression' (again 7). Each question has 4 possible responses. Responses are scored on a scale from 3 to 0. The maximum score is therefore 21 for depression and 21 for anxiety. A score of 11 or higher indicates the probable presence of the mood disorder with a score of 8 to 10 being just suggestive of the presence of the respective state. The 2 subscales, anxiety and depression, have been found to be independent measures. In its current form the HADS is now divided into 4 ranges: normal (0-7), mild (8-10), moderate (11-15) and severe (16-21). Anxiety score = sum of items 1, 3, 5, 7, 9, 11, and 13. Depression score = sum of items 2, 4, 6, 8, 10, 12, and 14.

Time frame:
8 Weeks
Reported as:
Mean · score on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
score on a scaleRufinamidePlacebo
Week 1-0.2 ± 2.66-0.1 ± 2.02
Week 2-0.4 ± 2.42-0.4 ± 2.69
Week 3-1.0 ± 3.14-0.5 ± 2.91
Week 6-1.4 ± 3.57-1.2 ± 3.20
Week 8-2.0 ± 3.61-1.6 ± 3.07
Last Observation-1.2 ± 3.74-1.4 ± 3.01
PrimaryChange From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.

The MADRS (Montgomery and Asberg 1979) is a clinician-rated instrument that measures the presence and severity of depression. This instrument consists of 10 items. Each item is rated on a defined step scale of 0 to 6 with anchors at 2-point intervals. The MADRS total score is the sum of the 10 items and ranges from 0 to 60. A high numeric rating shows a greater degree of symptom severity.

Time frame:
8 Weeks
Reported as:
Mean · score on a scale
Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.
score on a scaleRufinamidePlacebo
Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.15.7 ± 5.5116.4 ± 4.86
PrimaryChange From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)

Severity of illness is the first scale in the CGI. A rating is filled in by the investigator at the start of treatment based on a 0-7 point weighted scale. It goes from not assessed (0), to among the most extremely ill patients (7).

Time frame:
8 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)
score on a scaleRufinamidePlacebo
Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)4.5 ± 0.604.4 ± 0.56
PrimaryChange From Baseline Raskin Depression Scale.

It explores the extent to which an individual demonstrates depression on three sub-scales (rated 1-5): verbal self-report, behavior and secondary symptoms of depression. Scores range from 3-15, with higher scores indicating greater severity.

Time frame:
8 weeks
Reported as:
Mean · score on a scale
Change From Baseline Raskin Depression Scale.
score on a scaleRufinamidePlacebo
Change From Baseline Raskin Depression Scale.5.2 ± 1.225.3 ± 1.20
PrimaryChange From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed

The Covi Anxiety Scale is a simple 3 item scale for the assessment of severity of anxiety symptoms. The scale measures 3 dimensions: verbal report, behavior and somatic symptoms of anxiety. Each item scored on a scale of 1 - 5. (1)not at all, (2)somewhat, (3)moderately, (4) considerably, and (5)very much), hence the scale is a 5- to 15 point range. The three items are the patient's verbal report (feeling shaky, jittery, jumpy), observed behavior consistent with anxiety during the interview (e.g. appearing frightened, shaky, restless) and somatic complains (e.g., sweating, trembling, heart pounding). COVI Rating Scale total score is the sum of items 1 - 3.

Time frame:
8 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
score on a scaleRufinamidePlacebo
Screening10.7 ± 1.3910.5 ± 1.26
Baseline10.7 ± 1.3510.6 ± 1.33
Week 38.3 ± 2.518.1 ± 1.99
Week 67.5 ± 2.517.6 ± 2.21
Week 87.1 ± 2.507.4 ± 2.17
Last Observation7.7 ± 2.737.7 ± 2.29

Adverse events

Collected over 8 Weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rufinamide0/115 (0%)1/115 (0.9%)75/115 (65.2%)
Placebo0/114 (0%)1/114 (0.9%)72/114 (63.2%)
Most frequent serious events
Most frequent serious events
EventRufinamidePlacebo
Ecotopic PregnancyPregnancy, puerperium and perinatal conditions0/1151/114
Acute BronchitisInfections and infestations1/1150/114
Most frequent other events
Showing 10 of 24
Most frequent other events
EventRufinamidePlacebo
HeadacheNervous system disorders14/11522/114
NauseaGastrointestinal disorders10/11512/114
SomnolenceNervous system disorders12/11510/114
Upper respiratory tract infectionInfections and infestations7/1159/114
ConstipationGastrointestinal disorders8/1151/114
DizzinessNervous system disorders6/1157/114
Dry MouthGastrointestinal disorders6/1155/114
FatigueGeneral disorders4/1155/114
RashSkin and subcutaneous tissue disorders5/1150/114
DiarrhoeaGastrointestinal disorders3/1154/114

Baseline characteristics

ITT Population: Randomized and received at least one dose of the study drugs.

Age, Continuous
Age, Continuous(years)RufinamidePlaceboTotal
Mean38.4 ± 12.4735.6 ± 11.5337.0 ± 12.07
Sex: Female, Male
Sex: Female, Male(Participants)RufinamidePlaceboTotal
Female7681157
Male393372
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RufinamidePlaceboTotal
Hispanic or Latino121931
Not Hispanic or Latino10395198
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RufinamidePlaceboTotal
American Indian or Alaska Native011
Asian12820
Native Hawaiian or Other Pacific Islander011
Black or African American141731
White8269151
More than one race000
Unknown or Not Reported71825
Region of Enrollment
Region of Enrollment(participants)RufinamidePlaceboTotal
United States115114229
08

Study locations

2 sites
  • Carmen Research
    Atlanta, Georgia 30080, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45408, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 10 years 3 months after primary completion. A results delay was requested in Dec 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2008
First posted
Jan 16, 2008
Start
Mar 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results delay requested
Dec 3, 2009
Results first posted
Jan 23, 2019
Last update
Feb 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00595231
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Jan 16, 2008
Start date
Mar 2008
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jan 23, 2019
Last update
Feb 27, 2019

Study contacts

Christpher Kenney, MD
study chair · Biotie Therapies Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rufinamide

Start the discussion